XRB vs. SLB in Jail and at Re-entry: Pilot, Proof of Concept

Last updated: December 13, 2021
Sponsor: NYU Langone Health
Overall Status: Completed

Phase

4

Condition

Opioid Use Disorder

Treatment

N/A

Clinical Study ID

NCT03604159
18-00823
  • Ages 18-60
  • All Genders
  • Accepts Healthy Volunteers

Study Summary

This is a pilot proof-of-concept randomized controlled trial, open-label and unblinded, examining the feasibility and acceptability of Buprenorphine extended-release vs. daily sublingual buprenorphine-naloxone for the treatment of opioid use disorder in jail and at community re-entry.

Eligibility Criteria

Inclusion

Inclusion Criteria:

  • Adults >18yo incarcerated in NYC jails with known release dates.
  • DSM-V criteria for current opioid use disorder (DSM-IV opioid dependence).
  • Currently maintained on sublingual buprenorphine-naloxone in the NYC jail opioidtreatment program.

Exclusion

Exclusion Criteria:

  • Individual not interested in XRB treatment. Current SLB patients are otherwise bydefinition appropriate for XRB.
  • Pregnant or planning conception. A urine dipstick pregnancy (hCG) test will beadministered at baseline. The test detects human chorionic gonadotropin (hCG) in urinewith a sensitivity/specificity of: 25 mIU hCG/ml, >99%. Time to result is fourminutes. If negative, a urine pregnancy test will be administered bi-weekly thereafterto ensure that a participant is not pregnant
  • No severe or acute medical or psychiatric disability preventing safe studyparticipation or making follow-up unlikely.

Study Design

Total Participants: 52
Study Start date:
June 24, 2019
Estimated Completion Date:
May 04, 2020

Connect with a study center

  • Bellevue Hospital Center

    New York, New York 10016
    United States

    Site Not Available

Map preview placeholder

Not the study for you?

Let us help you find the best match. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.